Questions related to Antimicrobial Resistance
I have completed my study in major of Veterinary Science and working on Livestock Sector since last 5 years.
I would also like to collaborate with some researchers to develop my further research career. I'm wondering how others have found colleagues to collaborate with there?
Animal Anatomy, Histopathology, Neuroscience, Antimicrobial Resistance and Zoonotic diseases are my main areas of interest.
I am looking to analyze ARB and ARG from real surface water of marshland.
Drug-resistant "superbugs" are now found virtually everywhere. As a result, most of the bacteria are resistant to antibiotics. So, as researchers and scientists, what are the alternative ways that we can prevent this disaster? Is there any novelty?
Source: Review On Antimicrobial Resistance
I am treating E. coli at different AgNO3 concentrations in order to follow bacteria kinetic growth. The slope of the bacterial growth curve continuously decreased with increasing AgNO3 concentration. At low concentrations, the growth of bacteria was delayed and at higher concentrations, growth was completely inhibited.
My question is related to why bacteria are not reaching the same Max. OD600 after long-term silver exposure for concentration below MIC. Assuming that the stationary phase is often due to a growth-limiting factor such as the depletion of an essential nutrient, I would expect that all the curves reached the same OD600 at a certain point after bacteria re-growing. I was thinking one possible explanation could be that AgNO3 is inducing the expression of new genes required for survival under stress (e.g, high AgNO3 concentration, lack of nutrients or toxic byproducts).
Thank you in advance,
Hi! I've got the result of bacterial whole-genome sequencing, but it is not integrated into a complete linear sequence. Now I want to know whether a gene is on a plasmid or on a chromosome, and if it is on a plasmid, I want to know which plasmid it is on (eg, rep33). Are there any web tools or software recommendations? what should I do with the contigs? Thanks.
I have looked into it; however, found no useful information. MARDy can be used but it is not functional these days.
Do you prepare it from colistin sulfate powder + distilled water following the equation c1 v1 = c2 v2 then we can mix it with McConkey agar for the isolation of colistin-resistant Gram-negative bacteria.
We have some carbon nanoparticles and want to check antibacterial activity against drug-resistant bacteria. Before working on drug-tolerant bacteria, Are there any protocols or parameters for checking nanoparticles whether have the antibacterial capability on drug-resistant bacteria?.
How can I get the most related work on this area, as you know, One Health is a comprehensive and multisectoral approach to assess and examine the health of animals, humans and the environment and I want to include in this review Priority of Pathogens in Antimicrobial Resistance Surveillance in Veterinary (Animal), Human and Environmental sample from a One Health approach is discussed. GLASS priority pathogens include Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus, Streptococcus pneumoniae, Salmonella spp. and Shigella spp., were also. so, pls share your experience in it!
So my last year project is Drug Efflux Pumps and Persistence in Methicillin Resistant Staphylococcus aureus and we gonna focus on persister cells to study the path way of antimicrobial resistance...my question is how can i link bioinformatics and some coding to this project without requiring wgs cause it's not an option inside our lab !I need a small yet beneficial technique/ tools in small scale that i can learn and implement by my self .PS I love programming in general but im still new to bioinformatics so i need help to link my passion for coding and my field "biotechnology"
Hi everyone. I am requesting for researchers willing to share with me their recent publications on AMR in the dairy sector. I would like to engage and collaborate with researchers in this area.
I have a research proposal for AMA study- one health approach, grant opportunity needed and collaborators. Kindly share opportunities and funding houses
I am trying create a chromosomal integrated gfp reporter fusion in-frame downstream of a gene coding for a toxin in E. coli. I do not want to clone/express this fusion from a plasmid, since I want the fluorescence to be proportional to the toxin expression. In addition, if I express that from a plasmid, use of antibiotic selection to grow them in my downstream experiments will interfere with my conclusions. I am trying to monitor the appearance of persister cells in E. coli. Any suggestion will be highly appreciated.
Databases of antimicrobial resistance (AMR) genes have been well established, but I wonder is there any similar database of disinfectant resistance genes. Does anybody have any idea about this?
I need to investigate clonal typing of ESBL producing E. coli and antimicrobial resistance gene based on sequence assay? How is it possible and what kind of tool is required?
I have just been looking at:
Hsu, J. (2020). How covid-19 is accelerating the threat of antimicrobial resistance. BMJ, 369.
It sounds worrying. The threat of antibiotic resistance has been increasing year on year and now the added use of broad spectrum antibiotics in patients who are being treated with COVID-19, to stop secondary bacterial infection, is very concerning.
I am looking to use bioinformatics for characterisation of previously sequenced Bacillus isolates. Mainly focusing on characterising antimicrobial resistance, toxin genes, thermotolerance and nitrate reduction. I have no previous experience with bioinformatics.
Can anyone point to any studies (other than the one below) that suggest a loss of microbial diversity in a given habitat exacerbates the spread of ARGs, or that increasing microbial diversity (e.g. via inoculation) reduces ARGs?
And/or if you have any general thoughts on this, please leave comments.
I'm working on the virulence gene profile (sefA, pefA and lpfA genes) and the antimicrobial resistance gene profile (bla-CTX-M, bla-SHV and bla-TEM genes) of 95 Salmonella enterica samples.So basically for each sample, I have scored them for the presence or absence of each genes. Could you suggest the best stat analysis to correlate the presence of virulence and resistance genes? I'm thinking of using Fisher's Exact test for pairwise comparison (3 virulence genes x 3 AMR genes). Thank you so much!
In the latest publication of The Lancet Global Health, I noticed that still antimicrobial resistance remains as the biggest challenge of this planet to fight against infectious diseases. Why the global community fails to address the challenge despite different interventions around the Globe?
A 70 year female admitted to the ICU with UTI.
Report: Isolate- Serratia marcescens
Cefepime- MIC 4 microgm/ml
Imipenem- MIC less than 1 microgm/ml
By asking the question I wanna know whether gene present in one genera of bacteria coding for particular antibiotic resistance will also be present in another genera of bacteria. For eg whether qnr gene coding for fluroquinolone resistance will be same for Staphylococcus spp and E.coli or not.
Alternatives to current treatments for bacterial and viral infection
Please discuss your findings and thoughts on this.
In the face of antibiotic and antiviral resistance increasing worldwide are there other approaches than antibiotics to address this approaching crisis such as immunotherapies that enhance immune responses in infected patients? The impact of antibiotics on the world, about eighty years ago, revolutionized the treatment of bacterial infections just as antiviral therapy changed the prognosis of HIV infection. Despite the World Health Assembly adopting a resolution, in 1998, encouraging member states to address the problem of antimicrobial resistance and to take action.1 Following this, in 2000, the World Health Organization presented a global strategy for the containment of antimicrobial resistance, calling for a multidisciplinary and coordinated approach.2,3 The resources needed to implement the strategy are not available.
Some of alternative strategies against infection include gene therapies that enhance the immune response to infection and bacteriophage antibiotics as antimicrobial defenses. Prokaryotic gene therapy has been suggested to combat multidrug resistant bacterial infection and was in use pre-antibiotic (pre1929).
A pathogen that tends to develop resistance such as Staphylococcus aureus is responsible for about 260000 nosocomial infections in the USA and causes between 60000 and 80000 deaths annually. Resistance to the newer Streptogamins, where resistance is related to the horizontal transmission of SatA (Synercid), has already been documented in streptogammin fed poultry. Apart from the obvious lifestyle choices and dietary requirements for a healthy immune response to pathogens (reduced stress factors, increased antioxidant function). Once infected, could biomedical approaches to boosting innate immune responses an alternative to antibiotics and antiviral drugs, a similar strategy to some cancer gene therapy approaches that consist of protective immune response stimulation.
Currently, an immunotherapeutic is in the early stages of development and would work by using antibodies, which neutralizes Clostridium difficile. Development of immunotherapeutic is being considered to treat patients with difficult to treat bacterial infections.
Antiviral and antitumor therapy
Immunotherapy has been used to treat cancer for some time and some researchers have reported antiviral effects when using percutaneous, intrahepatic IL-12 gene therapy for hepatocellular carcinoma [Sangro B et al., 2004]. An adenoviral vector delivered this IL-12 gene and when delivered directly to the site of the tumour there was little evidence of hypersensitivity and autoimmune reactions. Antiviral effects have been reported in patients treated with IL-12 gene therapy for liver tumors. One issue arising from enhanced immune response such as systemic IL-12 and IFN gamma therapy to treat viruses such as HCV can cause drug-induced hypersensitivity.
As our understanding expands about innate and adaptive immune responses and immunotherapy techniques develop, could this knowledge be directed to investigating new approaches to treating some microbial infectious diseases by pooling our knowledge and resources collaboratively?
There is great therapeutic potential in antimicrobial peptides, part of the innate immune system, whose action is confirmed in animal models and indicates that host defense peptides are crucial for both prevention and clearance of infection. However there is an argument that using these peptides may advance microbial resistance to natural innate defenses.
It is said that ASP is an effective program in this era of rapidly growing antimicrobial resistance. It optimizes the management of microbial infections and reduces the chance of developing resistance and adverse events related to antibiotic use. What does it actually mean? How to organize and implement it?
I would like to understand the current landscape of patterns in various healthcare settings and outcome measure of current interventions that are available in LMICs for resistance (an epidemic?).
Of late the spotlight is again on the emergence antimicrobial resistance. Antibiotics have been widely used in dentistry both for therapeutic and prophylactic reasons. I personally feel that their use is rampant in the developing countries than developed economies but many disagree with me. What are your views on this topic along with the practice followed in your country and if any policy on Antibiotic prescribing practice by dentists exists in your country?
I would like to request to solve my problem regarding Antimicrobial resistance genes in Campylobacter isolated from poultry.
I am searching for reports on the prevalence of Colistin resistance gene particularly, mcr-1, 2 in Campylobacter. Unfortunately, I could not find any research article on it.
What's wrong with this? Did nobody work on it? If yes, then why?
It would be greatly appreciated if anybody provides any report of mcr genes in Campylobacter, or clarify the above questions.
Thanks in advance.
Md. Mehedi Hasan
Bangladesh Agricultural University, Bangladesh
Can someone please help me with this question? Why is bacteria isolate obtained from small mammals sampled in human induced habitats likely to be more resistant to antibiotic drugs than isolates obtained from small mammals sampled in their natural habitats?
Hi. If I were to supplement a 500ml media with two different antibiotics of the same concentration (10μg), how do I make sure the concentration of each antibiotic doesn't change?
Apparently, my strain (which is ampicillin-resistant and tetracycline susceptible) grows on BHI agar supplemented with 10μg ampicillin and does not grow on BHI agar supplemented with 10μg tetracycline, which is fine. However the bacteria grows on BHIA supplemented with tet + amp, both 10μg. Could this possibly be caused by any change in the antibiotics concentration?
For my current literature review I'm still looking for numbers of antibiotics used in agriculture / livestock/ animal production in developing countries. We already know about bad or no data collection in many countries and I have read a lot of "over the counter sales" etc. but rather in human than in veterinary medicine. Unfortunately, I didn't find any numbers of used antitbiotics in developing countries or any data about antimicrobial resistance of livestock in developing countries. Any help would be appreciated :)!
Thanks in advance!!!
I am looking for seminar topic as well as gathering new information for the community.
Hi! I have done E-TEST for some bacteria such as Bacillus, Lysinibacillus and Paenibacillus. How can I find the breakpoints of them?
Do any body have ever observed or know Sugar-Sweetened Beverages (SSB) or Carbonated Beverages have any correlation with Antimicrobial Resistance. '
Your kind help will be always highly appreciated.
I performed whole genome NGS (Mi-seq platform) of bacteria to identify antimicrobial resistance genes.
bacterial genome assembled with A5-miseq and I want to separate contigs with plasmid origin.
I`m new to the field of Bioinformatics and any recommendation is highly appreciated.
Hi, I am going to perform a conjugation experiment. I have a donor that have antimicrobial resistance and I wonder how to choose my recipient? and how to mark it? can I use rifampicin as a marker? If yes, is there a fixed protocol for that or just selecting the bacteria on agar plates that is supplemented with increasing rifampicin concentration? I will use this donor and I will try to conjugate it with different strains of bacteria.
There will be a book citation index as the one exists for articles?? I will highly appreciate if someone could recommend me a couple of reputed publisher (free of cost or with affordable cost) for publishing a book in the area of Microbiology (antimicrobial resistance).
Am trying to transfer some genes from staphylococcus aureus to RN42200 strain, I need a commercial available expression or cloning vector which is suitable to clone these genes and still be able to be transformed to another staph. strain and to be still expressive.
Antimicrobial resistance is a growing threat. Scientific community is working on different strategies to tackle this problem. Chalcones are known to have antimicrobial activity. Either these can be used to treat the resistant infections or not? If yes, is there any option to use these in combination with some other drugs like antibiotics?
One Health is "the collaborative effort of multiple disciplines – working locally, nationally and globally – to attain optimal health for people, animals and the environment". In what specific ways this approach may help us to contain antimicrobial resistance and what should be our role in it?
Antimicrobial resistance (AMR) is a global problem to the fight against most infectious disease. Our planet costs a lot because of widespread AMR. Scientists in the field urged that stakeholders need to promote rational use of drugs to slow down the effect of AMR. Among the different steps to be considered, establishing antimicrobial stewardship is very crucial. I am wondering how this could be started, what are the different steps to follow....?
The human microbiota/ normal flora comprises the populations of microbial species that live on or in the human body. The biggest populations of microbe reside in the gastrointestinal tract. Evidences showed that the gut is the epicentre of antibiotic resistance. How these microbial population (that are estimated to be over 1,000 different species) contribute for antimicrobial resistance?
There are two approaches for molecular antimicrobial resistance (AMR) surveillance: 1.Typing-based, in which resistance is predicted by association with genotype, and 2. The direct detection of genetic markers of AMR.
If the prevalence of Neisseria gonorrhoeae is low in a city(for example 25-30 isolates during 6 month sampling), which approach is suitable for molecular AMR surveillance?
Hydrolysis of β-lactam antibiotics by β-lactamases is the most common mechanism of resistance for this class of antibacterial agents in clinically important Gram-negative bacteria. Because penicillins, cephalosporins, and carbapenems are included in the preferred treatment regimens for many infectious diseases, the presence and characteristics of these enzymes play a critical role in the selection of appropriate therapy.
- As I am also going to work on animal handlers and antimicrobial resistance hence I just want it as reference and also for review. This will give me more insight.
Mycobacterium abscessus is one of the hardest to treat non-TB mycobacteria due to antimicrobial resistance, side effects of therapy, and patient comorbidities. It is even harder to treat in certain patient populations such as people with cystic fibrosis. I am interested in YOUR EXPERIENCES in treating M.abscessus especially in CF patients. Any adjuvant therapies, synergestic antimicrobial combinations, or specific measures taken, especially in early disease where there is no focal areas to consider surgical resection. P.S treatment guidelines attached
which software may I use to analyze whether specific antibiotic resistance genes are present or not (e.g. mecA, blaZ) or whether virulence genes (such as the shiga toxins (Stx1 and Stx2) or the Staphylococcus aureus Panton-Valentine leukocidin) are present?
- I am not allowed to load data to a server or a cloud (thus I am not allowed to use e.g. ResfInder or to use RAST to annotate the genome)
- I was trying the CLC Microbial Genomics Module . It works fine but as I do not use CLC genomic workbench for any other analysis, it`s getting quite expensive.
Which other tools may use? I only have very little experience in using command line programs (I only learned how to use R. However, it`s several years ago...) and we only have windows here. However, I am willing to learn how to use command line tools and maybe it is possible to use a virtual box in order to be able to run softwares that are not running on windows.
Recently we have got approved our Concept Note on Therapeutics interventions for the treatment of various disease conditions caused by AMR bacteria under NAHEP Programme of ICAR funded by World Bank.
The concept theme is based on our recent research on Synergistic Interactions of herbal antimicrobials with each other and with antibiotics with the aim to develop Herbibiotics (synergistic combination of Herbal antimicrobials) and Combiotics (synergistic combinations of Antibiotics and herbal components).
Under the programme, we are searching for international collaboration specifically for faculty and Student exchange programme to further the research and keep the hope against emerging drug resistance through trained human resource to deal with the problem. In recent years we have identified feasible synergism between important antibiotics and herbal antimicrobials, useful synergism between two or more herbal antimicrobials and identified the utility of some herbal components as effective antimicrobials. Besides, we are able to locate and identify genes responsible for herbal antimicrobial resistance and synergism.
Your Early response is anticipated as we need to give the names of collaborators within next two weeks.
Thanking you with regards and with anticipation for participation.
Diameter of the disk = 8mm
CAZ = 20mm
CAZ-CLV = 30mm
CAZ = no inhibition (0mm????)
CAZ-CLV = 10mm
We would know that isolate A tested positive for ESBL
since the diameter is greater than 5mm with clv
However, for isolate B, this is harder for me to determine
since I can’t make a judgement on whether the diameter
with Caz-clv should be taken to be more than 5mm,
even though the observable increase in diameter is only 2mm
owing to the disk being 8mm itself
(10mm – 8mm = 2mm; ESBL-ve)
OR (10mm – 0mm = 10; ESBL+ve)
(should Isolate B be counted as an ESBL producer???)
What is the suitable regression to be used if I have binary independent variables and also the dependent variables ar binary ? i.e. yes/no ?
I am checking whether the presence/absence of virulence genes is associated with the presence/absence of antimicrobial resistance genes. I coded them all as 0/1. ?
What are the suitable recommendations to have only one inhibition zone around the antibiotic disc? the problem in the attached file is having two zones around one disc? ( the work was done under restricted conditions ).Thank you in advance.
From my previous screening study, Acinetobacter baumannii was found to be highly resistant to many antibiotics tested. I think it should be some guidelines or documents for microbiologists and doctors about the effective antibiotics against this bacterium. Thanks
Does any body know any standard protocols used for determining such effects?To make things clear, the microbes in the environment are exposed perhaps to mixed pharmaceuticals at low concentration. this might theoretically accelerate development of drug resistance. So, should any body know how to approach such issues ...please assist
Any body knows whether it exisits a data base including spatial and temporal information on occurrence of antibiocrobial resitant genes in the environment?
The only databse I have found is the ARDB - Antibiotic Resistance Genes Database. But it seems to be a DNA sequece type data-base. As far as I saw, it does not include information about where and when resistant genes where found.
Invitro hemolysis of human/sheep blood is tested in order to detremine biocompatibility. my question is that why only erythrocytes?? why cant any other cell be tested for checking biocompatibility?? if there is a relation between antimicrobial biocompatibility and hemolysis or if there is any special significance of hemolysis in such aspects, please let me know
Are there any recommendations or specific protocols for performing Modified Hodge test? Can I perform it without positive control? Thank you.
If we have to treat some biofilm or persistent cell population then why researchers are trying to test their killing concentrations which are far beyond the clinical achievable level. e.g. For treating S. aureus why 50-100X MIC which is nearly 25-50 ug/ml. And we knew that Cmax is not going to be above 4 ug/ml.
Self-medication is a human behavior in which an individual uses a substance or any exogenous influence to self-administer treatment for physical or psychological ailments.
The most widely self-medicated substances are over-the-counter drugs used to treat common health issues at home, as well as dietary supplements. These don't require a doctor's prescription to obtain.Excessive and not always proper use of antibiotic is a serious problem, of which antimicrobial resistance, currently cause for worldwide concern, is the major one. How can we reduce self-medication with antibiotics?
Resistant microorganisms (including bacteria, fungi, viruses and parasites) are able to withstand attack by antimicrobial drugs, such as antibacterial drugs (e.g. antibiotics), antifungals, antivirals, and antimalarials, so that standard treatments become ineffective and infections persist, increasing the risk.
It is an increasingly serious threat to global public health that requires action across all government sectors and society.Antimicrobial resistance is present in all parts of the world. New resistance mechanisms emerge and spread globally.
Can someone Provide/share some innovative ideas to combat AMR